Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Scandinavian Journal of Gastroenterology Année : 2022

Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study

1 Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre]
2 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
3 CHU Amiens-Picardie
4 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
5 Service d'Hépato-gastro-entérologie [CHRU Nancy]
6 CHU Nice - Centre Hospitalier Universitaire de Nice
7 University Hospital of Montpellier
8 CRI (UMR_S_1149 / ERL_8252 / U1149) - Centre de recherche sur l'Inflammation
9 Service de Gastroentérologie [Hôpital Beaujon]
10 Hôpital Nord [CHU - APHM]
11 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
12 INFINITE (Ex-Liric) - Institute for Translational Research in Inflammation - U 1286
13 Hôpital Cochin [AP-HP]
14 Hôpital Robert Debré
15 HCL - Hospices Civils de Lyon
16 AP-HP - Hopital Saint-Louis [AP-HP]
17 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
18 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
19 ADEN - Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau
20 IRIB - Institute for Research and Innovation in Biomedicine
21 UNIROUEN UFR Santé - UNIROUEN - UFR Santé
22 Service d'Hépato-Gastroentérologie [CHU Rouen]
23 Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
24 CHU Saint-Antoine [AP-HP]
25 CHU Clermont-Ferrand
26 NuMeCan - Nutrition, Métabolismes et Cancer
27 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
28 CHU Nantes - Centre hospitalier universitaire de Nantes
29 Institut des Maladies de l'Appareil Digestif
30 CHU Caen
31 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)
Stéphanie Viennot
  • Fonction : Auteur

Résumé

INTRODUCTION: There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. METHODS: We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events. Propensity scores weighted comparison was applied. RESULTS: In total, 121 patients were included in the vedolizumab group and 97 were included in the ustekinumab group. At week 14 and week 52, in the weighted cohort, no difference was found between vedolizumab and ustekinumab for steroid-free clinical remission (OR = 0.55 [0.21-1.41], p\,=\,.21 and 0.94 [0.40-2.22], p\,=\,.89, respectively). There was no difference between vedolizumab and ustekinumab for secondary outcomes such as clinical remission, hospitalization, UC-related surgery, treatment persistence and serious and infectious adverse events. CONCLUSION: In patients with UC for whom anti-TNF therapy failed, no difference was found between vedolizumab and ustekinumab after propensity scores weighted comparison. Further studies are required to determine predictive factors of the efficacy of both biological agents.
Fichier non déposé

Dates et versions

hal-03723440 , version 1 (14-07-2022)

Identifiants

Citer

Antoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, Jérôme Filippi, Romain Altwegg, et al.. Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study. Scandinavian Journal of Gastroenterology, 2022, 57 (12), pp.1454-1462. ⟨10.1080/00365521.2022.2095668⟩. ⟨hal-03723440⟩
106 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More